BioMarin Pharmaceutical
Inc. BMRN today announced that it has submitted the Vimizim Marketing
Application (MA) to the Agência Nacional de Vigilancia Sanitaria (ANVISA), or
the National Health Surveillance Agency Brazil. Assuming priority review
status, based on orphan drug status in the U.S. and EU, an approval decision
from ANVISA is anticipated in mid 2014.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in